Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp (KTTAW) is a clinical-stage biotechnology company pioneering treatments for central nervous system disorders and RASopathies. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access verified news about the company’s pipeline progress, including its lead candidate PAS-004 (a macrocyclic MEK inhibitor), trial design updates, and collaborations. Our curated collection features press releases on:
• Clinical trial phases
• Research partnerships
• Regulatory submissions
• Scientific publications
Bookmark this page for centralized access to Pasithea’s latest advancements in neurofibromatosis, ALS, and schizophrenia research. Check regularly for objective updates on therapeutic innovations and corporate developments shaping the biotechnology landscape.
Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.
The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.
Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its Chairman, Prof. Lawrence Steinman, will receive the 2023 Pioneer in Medicine Award for significant contributions to brain mapping and therapeutics at the 20th Annual Gathering for the Cure on February 17, 2023. This award is presented by the Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping Foundation, recognizing pioneering work in fields like multiple sclerosis (MS). The company is focusing on developing a proprietary engineered DNA plasmid vaccine, PAS-002, targeting GlialCAM for MS treatment, affecting over 2.3 million people worldwide.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced a partnership with WuXi STA to manufacture the active pharmaceutical ingredient for its MEK Inhibitor PAS-004, targeting Neurofibromatosis Type 1 (NF1). This collaboration is pivotal as the company aims to submit its Investigational New Drug (IND) application to the FDA in the second half of 2023, following successful pre-clinical testing. PAS-004 has received orphan drug designation and is expected to commence a Phase 1 clinical trial soon. WuXi STA is recognized for meeting rigorous global quality standards, reinforcing the development of PAS-004 into a promising therapeutic option for CNS disorders.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced the results of its Special Meeting of Stockholders held on December 9, 2022. Approximately 67% of stockholders voted against proposals to remove the current Board of Directors, representing about 12.7 million shares or 44% of total shares. This decision allows the current Board to continue overseeing the company's strategy. CEO Dr. Tiago Reis Marques expressed gratitude for stockholder support and commitment to developing innovative treatments for CNS disorders, including ALS and Multiple Sclerosis.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has reached a Settlement and Cooperation Agreement with the Camac Group, resolving all litigation issues. The Camac Group will observe a three-year standstill and has agreed to sell 3,205,282 shares of common stock at $1.0003 each, reflecting the five-day average price. Pasithea will also reimburse certain expenses. CEO Tiago Reis Marques expressed optimism about this agreement, stating it allows the company to focus on advancing its CNS therapies. The Board of Directors will continue overseeing the company's strategy following a recent Special Meeting.
